The investigators plan to conduct an R61/33 hybrid type 2 implementation-effectiveness trial that includes 1) a one-year exploratory R61 phase that will enable the development of the intervention protocol needed for the R33 trial phase including concrete R61 phase milestones; 2) a four-year R33 phase that will include a concurrent implementation evaluation and a randomized control trial.

Start Date01 Jun 2026

Sponsor / Collaborator

Duke University

[+4]

NCT07176351

/ Not yet recruitingPhase 4IIT

Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic: A Pilot Study

This exploratory project will assess the acceptability and feasibility of monthly extended-release subcutaneous buprenorphine (BRIXADI; XR-B) to treat opioid use disorder (OUD) among persons in the community receiving care on a mobile pharmacy clinic (MPC).
Participants who are interested in initiating monthly or weekly injections of subcutaneous XR-B (BRIXADI) as a treatment for their OUD will be enrolled in a 6-month study assessing the acceptability and feasibility of receiving XR-B on an MPC.

Start Date01 Mar 2026

Sponsor / Collaborator

Yale University

[+1]

NCT05339256

/ Not yet recruitingPhase 2IIT

A Randomized, Controlled Trial of Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual in the Treatment of Opioid Use Disorder

This study will compare in-person induction and maintenance dosing of sublingual buprenorphine to induction and maintenance dosing of sublingual buprenorphine through comprehensive telehealth sessions and telehealth medication for opioid use disorder (MOUD).

Start Date01 Feb 2026

Sponsor / Collaborator

The New York State Psychiatric Institute

[+1]

100 Clinical Results associated with Buprenorphine

100 Translational Medicine associated with Buprenorphine

100 Patents (Medical) associated with Buprenorphine

10,444

Literatures (Medical) associated with Buprenorphine

01 Dec 2026·Current Pain and Headache Reports

Perioperative Management of Patients on Buprenorphine

Review

Author: Mydlo, Nicholas ; Ng, Jessica ; Hines, Roberta ; Silverman, Matthew ; Hickey, Thomas ; Vadivelu, Nalini ; Chowdhari, Sean ; Kodumudi, Gopal ; Thomas, Donna-Ann ; Dextras, Christopher

PURPOSE OF THE REVIEW:

Our review discusses the pharmacologic profile of buprenorphine, then dives into the current literature regarding buprenorphine's use to treat chronic pain, opioid use disorder, and acute postoperative pain. We aim to focus on how that literature may influence the perioperative management of patients on buprenorphine and prompt reconsideration of buprenorphine as a frontline opioid analgesic.

RECENT FINDINGS:

Buprenorphine has been used effectively for both acute and chronic pain management, for the treatment of opioid withdrawal, and for the treatment of opioid use disorder due to its unique pharmacological profile. Historically, there has been controversy over the best practice recommendations for buprenorphine use in the perioperative setting, though the data now overwhelmingly refutes the full discontinuation of buprenorphine preoperatively. It has also been seen in recent times that buprenorphine is at least as effective as usual care opioids for acute pain management, with important safety advantages. Expanding our analgesic toolkit to more thoroughly understand the unique mechanism of action and properties of buprenorphine is paramount in our treatment of perioperative pain in both opioid-naïve and opioid-tolerant patients.

01 Jun 2026·Addictive behaviors reports

Influence of residential greenness and season on discontinuation of medication treatment for opioid use disorder across rural to urban community types

Article

Author: Bandeen-Roche, Karen ; Schwartz, Brian S ; Nordberg, Cara M ; DeWalle, Joseph ; Poulsen, Melissa N ; Berrettini, Wade

Introduction:

Medications for opioid use disorder (MOUD) are standard of care for opioid use disorder (OUD), but high rates of treatment discontinuation limit their impact on recovery. Nature exposure and engagement holds promise as a potential adjunctive treatment to MOUD through stress reduction and mental health benefits. This study evaluated whether nature exposure influenced MOUD treatment participation by analyzing associations of residential greenness with MOUD discontinuation across a diverse geography in Pennsylvania, while considering interrelated factors-season and community type.

Methods:

We analyzed electronic health records from 2,570 adults receiving MOUD from an outpatient addiction treatment program. Weekly MOUD participation was derived from medication days' supply of buprenorphine or naltrexone. Average weekly greenness (normalized difference vegetation index) was assigned to buffers surrounding participants' residential address. We applied mixed-effects logistic regression of pooled person-weeks in treatment to model the odds of MOUD discontinuation, clustered by patient and with robust standard errors.

Results:

In models adjusted for sociodemographic factors, residential greenness was not associated with MOUD discontinuation. We observed associations of season with MOUD discontinuation: compared to spring weeks, the odds of MOUD discontinuation were 20-27% higher during summer, fall, and winter weeks. In season-stratified models, we observed a non-linear association of greenness and MOUD discontinuation during the spring season.

Conclusions:

Understanding factors contributing to MOUD discontinuation is essential to improving recovery outcomes for those with OUD. Findings suggest that passive greenness exposure may have little influence on MOUD participation but identified the potential importance of season on MOUD outcomes.

01 Jun 2026·Addictive behaviors reports

Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study

Article

Author: Suh, Rebecca ; Sofuoglu, Mehmet ; De Aquino, Joao P ; Costa, Gabriel P A

While medications for opioid use disorder (MOUD) effectively treat opioid use disorder (OUD), concurrent pain management remains challenging. Cannabidiol (CBD) shows promise in both pain management and OUD treatment. This open-label, proof-of-concept study aimed to evaluate the safety and tolerability of cannabidiol (CBD) and explore its utility for pain sensitivity using quantitative sensory testing (QST) among individuals with co-occurring OUD and chronic pain. Seven individuals with OUD receiving methadone or buprenorphine and experiencing chronic pain completed three test sessions with ascending oral CBD doses (400 mg, 800 mg, 1200 mg). QST analyses for pain sensitivity showed no significant main effects of CBD dose or time but revealed a significant MOUD x CBD dose interaction for heat pain threshold and tolerance. Post-hoc comparisons indicated that participants receiving buprenorphine exhibited significantly higher heat threshold (400 mg) and heat tolerance (800 mg) compared to those receiving methadone. Descriptively, the 400 mg CBD dose was associated with the most favorable pain response patterns across several QST measures in the buprenorphine group. CBD was well-tolerated across all doses; no serious adverse events, changes in subjective effects, or adverse cognitive effects on verbal memory were reported. In conclusion, this pilot study offers preliminary indications that CBD's impact on pain sensitivity varies by dose and MOUD type, notably with potential benefits at 400 mg for individuals on buprenorphine. Coupled with its demonstrated safety and tolerability, these findings support future larger, placebo-controlled randomized trials to confirm CBD's therapeutic utility for pain in this population.

115

News (Medical) associated with Buprenorphine

25 Feb 2026

·www.einpresswire.com

Renew Health Expands Evidence-Based Addiction Care and Telehealth Services Across New Mexico

Award-winning Renew Health launches statewide outpatient and telehealth services, offering compassionate, medication-assisted treatment for long-term recovery. ROSWELL, NM, UNITED STATES, February 25, 2026 / EINPresswire.com / -- In communities across New Mexico, the need for accessible, effective addiction treatment has never been greater. Renew Health Addiction Recovery Services is stepping up to meet that need by providing compassionate, evidence-based care for individuals and families impacted by substance use disorders. With outpatient and telehealth services available statewide, Renew Health is helping people begin and sustain recovery on their own terms. Renew Health offers a full continuum of alcohol and drug addiction treatment, including care for opioid use disorder, alcohol dependency, prescription drug misuse, methamphetamine addiction, cocaine use, and more. The center specializes in Medication-Assisted Treatment (MAT), combining FDA-approved medications such as buprenorphine and naltrexone with therapy and behavioral health support to address both the physical and psychological aspects of addiction. “At Renew Health, we know recovery isn’t one-size-fits-all,” said a company representative. “Every person who walks through our doors - or logs in through telehealth - has their own story. Our role is to meet them where they are, remove barriers to care, and support their journey with respect, dignity, and evidence-based treatment.” Founded by Nurse Practitioner Trent Carter, Renew Health was created to address the significant treatment gaps facing New Mexico communities, particularly in rural and underserved areas. By offering both in-person outpatient services and secure online telehealth treatment, Renew Health ensures that individuals can access care without long waitlists, overnight stays, or unnecessary disruptions to their daily lives. Patients at Renew Health receive a comprehensive assessment upon intake, allowing the care team to develop a personalized treatment plan tailored to each individual’s needs and goals. Services include Medication-Assisted Treatment, Cognitive Behavioral Therapy (CBT), mental health counseling, family therapy, and care coordination. This whole-person approach focuses not only on sobriety but also on long-term stability, mental wellness, and rebuilding healthy relationships. Renew Health’s clinic serves as a central hub for Roswell addiction recovery, offering accessible, community-based support to individuals throughout the region. The center’s outpatient model allows patients to remain connected to their families, jobs, and support systems while receiving consistent, high-quality care. Telehealth services further extend that reach, ensuring treatment is available to people across New Mexico, including those in remote or underserved areas. What sets Renew Health apart is its commitment to care without punishment. Substance use disorder is treated as a chronic medical condition, not a moral failing. If relapse occurs, the focus remains on reassessment, support, and continued progress rather than judgment or exclusion. The center also works closely with patients to navigate insurance coverage, including Medicaid, helping reduce financial barriers to treatment. The organization’s impact has not gone unnoticed. Renew Health was recently recognized as the “Best Drug and Alcohol Rehab Center in New Mexico in 2024” by Addiction Group, an award that reflects both clinical excellence and meaningful patient outcomes. “Addiction affects millions of people and countless families,” the representative added. “We’re here because we believe recovery is possible, and because every individual deserves access to care that is compassionate, effective, and respectful.” Renew Health Addiction Recovery Services is located at 207 N Union Ave, Roswell, NM 88201, and is open Monday through Friday from 9 a.m. to 5 p.m. To learn more or schedule an appointment, call (575) 363-3189 or 575-363-HELP, or email info@renewhealth.com. ### About Renew Health Addiction Recovery Services: Renew Health Addiction Recovery Services provides compassionate, evidence-based outpatient and telehealth addiction treatment across New Mexico. Led by board-certified addiction specialists, the organization offers Medication-Assisted Treatment (MAT), behavioral therapy, mental health services, and community-based support for individuals struggling with substance use disorders. Founded with a mission to reduce barriers to care and rebuild lives one family at a time, Renew Health is committed to delivering accessible, personalized treatment that supports long-term recovery. Trent Carter Renew Health +1 575-363-4357 email us here Visit us on social media: Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

22 Feb 2026

·www.biospace.com

AltaPointe Health Study Finds Low-Dose Ketamine Helps Fentanyl Users Start Buprenorphine Without Severe Withdrawal

MOBILE, Ala. , Feb. 20, 2026 /PRNewswire/ -- Drug overdoses caused an estimated 73,000 U.S. deaths last year, with the synthetic opioid fentanyl causing the majority of fatal overdoses. A new study finds Ketamine eases fentanyl withdrawal and speeds recovery Buprenorphine, a medication for treating opioid-use disorder, is effective and saves lives, but people often avoid it for fear of painful opioid withdrawal symptoms that can occur when starting the medication. This is particularly true among fentanyl-dependent individuals, many of whom report that buprenorphine initially makes their symptoms worse before abating. Withdrawal symptoms of muscle aches, vomiting, diarrhea, sweating, chills, restlessness and anxiety can increase in severity for up to five days. Findings published Feb. 11 in the journal Addiction Science and Clinical Practice showed that a new strategy of using an extremely low intramuscular dose of the anesthetic ketamine before starting buprenorphine led to a rapid, large reduction of fentanyl withdrawal symptoms in nearly all patients, without any side effects. Most patients could then immediately start buprenorphine without a return of withdrawal symptoms. "It has been a challenge helping individuals dependent on opioids in the fentanyl era, and this simple, inexpensive and highly effective treatment strategy has a lot of promise in helping people transition to buprenorphine safely and comfortably. The hope is that this will be another opportunity to make a dent in the ongoing opioid overdose epidemic," said first author, Dr. Luke Engeriser, deputy chief medical officer for AltaPointe Health and associate professor at the University of South Alabama. Dr. Engeriser designed the study which followed 50 patients experiencing fentanyl withdrawal at AltaPointe's 24-hour Behavioral Health Crisis Center in Mobile, Alabama. Over half of the patients were completely free of withdrawal symptoms within an hour of starting the ketamine-assisted buprenorphine therapy, and the average length of stay at the facility dropped from 66 hours to seven hours. Almost all patients were stable enough for discharge from the crisis center within hours after the first buprenorphine dose. The ketamine treatment costs 44 cents per patient.  In emergency departments, a high dose of ketamine, causing intense drowsiness, has been shown to reverse withdrawal symptoms after starting buprenorphine. This study was the first demonstration that a low dose of ketamine could both relieve fentanyl withdrawal and prevent renewed symptoms after starting buprenorphine. The researchers think this strategy could be adapted for use in many settings where buprenorphine treatment is offered, including inpatient, emergency department, residential treatment, withdrawal management, crisis center, outpatient, prison/jail or mobile clinics, and warrants further study in these settings. Importantly, since ketamine is a controlled substance, injection by a healthcare provider is safer than self-administration as it avoids the risk of misuse by patients. "I have seen the impact this protocol has had in quickly and relatively comfortably transitioning patients from dangerous use patterns onto a path to recovery and stability. It has been very gratifying to provide such a benefit to the person in front of me while contributing to a shift in how many others receive care," said Dr. Evan Chavers, a co-author of the study and chief resident of the University of South Alabama psychiatry residency. This report of the use of sub-dissociative dose ketamine to block withdrawal symptoms affirms and greatly strengthens findings from a previously published pilot study from the senior author of this week's report, Dr. Lucinda Grande, a primary care doctor in Lacey, Washington and a clinical associate professor of family medicine at the University of Washington School of Medicine, who specializes in chronic pain and addiction treatment. The paper is available at: View original content to download multimedia: SOURCE AltaPointe Health Systems

04 Feb 2026

·www.drugs.com

RFK Jr. Expands Faith-Based Addiction Care as Drug Use and Homelessness Rise

WEDNESDAY, Feb. 4, 2026 — Amid mounting drug use and homelessness in U.S. cities, Health Secretary Robert F. Kennedy Jr . said the federal government is overhauling the way it fights addiction. The strategy announced Monday includes a new focus on faith-based recovery programs and increased access to medication treatment. Kennedy announced plans to open federal funding to religious organizations that provide addiction care, while launching new programs aimed at helping people who are homeless and struggling with mental illness or substance use get long-term support. Kennedy, who has spoken openly about overcoming a 14-year heroin addiction with help from 12-step programs, said the current health system has often caused people to “cycle endlessly between sidewalks, emergency room visits, jails and mental hospitals and shelters.” He said substance use plays a major role in homelessness and called for more intensive recovery programs that help people learn how to live in the community and find jobs. Kennedy said that he had seen many people turn their lives around in “sober homes and recovery houses.” As part of the plan, federal funding, including state opioid response grants, will now be open to faith-based organizations. “We are bringing faith-based providers fully into this work,” Kennedy said. “This is a chronic disease. It’s a physical disease, it’s a mental disease, it’s emotional disease, but above all, it’s spiritual disease. And we need to recognize that and faith-based organizations play a critical role.” At the same time, Kennedy announced a major expansion of access to medications for opioid use disorder. States and native tribes will be allowed to use federal child protection funds to help addicted parents receive treatments like buprenorphine , methadone and naltrexone . The goal? To keep families together and avoid the need for children to enter foster care. Dr. Yngvild Olsen , formerly with Substance Abuse and Mental Health Services Administration, told The New York Times that the change “has the potential to save lives.” Kennedy also introduced a new $100 million pilot program called STREETS, an acronym for Safety Through Recovery, Engagement and Evidence-Based Treatment and Supports. The program is designed for people who are homeless and living with addiction or serious mental illness. “We’ll engage people continuously, from first contact on the street through recovery, through employment and through self-sufficiency,” Kennedy said. “Law enforcement, courts, housing providers and health care systems will work as one team, so people will no longer fall through the cracks.” He also announced a $10 million grant to expand assisted outpatient treatment, which allows courts to require people with serious mental health issues to receive care in the community. Tom De Vries , president of Citygate Network, which represents about 330 Christian rescue missions, said many faith-based groups are adjusting to the opportunity of receiving federal support. “The government has reached out to us and invited us into the process more than we had been previously,” he said, adding that some organizations are weighing funding opportunities against restrictions on religious practices — for instance hiring only Christians. The administration is also moving away from the government’s long-standing “Housing First” approach. It focused on placing people in permanent housing and then offering, but not mandating, treatment. Rev. Andy Bales , former CEO of the Union Rescue Mission in Los Angeles, said faith-based providers were often shut out under that system. “They wrote us off,” he told The Times . “It was brutal.” Bales also warned that recent Trump administration policy shifts threatened to send up to 170,000 formerly homeless people back onto the streets. “It not only scared stakeholders, but it caused Republican senators to intervene and say, ‘This is too aggressive,’ ” he said. “I don’t think it’s going to be rolled out successfully unless the tone changes, and there is some compromise and diplomacy carried out.” Sources The New York Times, Feb. 2, 2026

100 Deals associated with Buprenorphine

External Link

KEGG	Wiki	ATC	Drug Bank
D07132	Buprenorphine	N07BC01	DB00921

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Opioid-Related Disorders	United States	Braeburn, Inc.	23 May 2023
Opium Dependence	European Union	Camurus AB	20 Nov 2018
Opium Dependence	Iceland	Camurus AB	20 Nov 2018
Opium Dependence	Liechtenstein	Camurus AB	20 Nov 2018
Opium Dependence	Norway	Camurus AB	20 Nov 2018
Opioid abuse	United States	Indivior, Inc.	30 Nov 2017
Pain	United States	Purdue Pharma LP	13 Oct 2017
Chronic Pain	United States	Purdue Pharma LP	30 Jun 2010

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Analgesia	Phase 3	-	Purdue Pharma LP	01 Nov 2011
Pain, Postoperative	Phase 3	-	Purdue Pharma LP	01 Nov 2011
Intervertebral Disc Disease	Phase 3	China	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Aug 2009
Musculoskeletal Pain	Phase 3	China	Beijing Mengdi Pharmaceutical Co. Ltd.	01 Aug 2009
opioid dependence methadone	Phase 3	United States	Titan Pharmaceuticals, Inc.	01 Sep 2008
Osteoarthritis, Spine	Phase 3	United States	Purdue Pharma LP	01 Apr 2004
Osteoarthritis, Knee	Phase 3	United States	Purdue Pharma LP	01 Jun 1999
Low Back Pain	Phase 3	United States	Purdue Pharma LP	01 Apr 1997
Osteoarthritis	Phase 3	United States	Purdue Pharma LP	01 Nov 1996
Irritable Bowel Syndrome	Phase 2	United States	OrphoMed, Inc.	22 Nov 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04225598 (Pubmed \| JAMA)	Phase 2	Opioid abuse	1,994	Extended-release buprenorphine	wfszcxemlu(gttoripmqg) = ytscievllv rutpwymmge (gfnaatoaau ) View more	Similar	11 Feb 2026
				Sublingual buprenorphine	wfszcxemlu(gttoripmqg) = kldpamzvaq rutpwymmge (gfnaatoaau ) View more
NCT04995029 (CTgov)	Phase 4	Opioid-Related Disorders \| Opioid abuse	785	Extended-release Buprenorphine (Maintenance Phase: Extended-release Buprenorphine 100 mg)	uwjrxyrxev = bvjjgjinbl drfnlxkaut (vtxeywdkha, rlzsrmleom - bxhqjbqqej) View more	-	25 Sep 2025
				Extended-release Buprenorphine (Maintenance Phase: Extended-release Buprenorphine 300 mg)	uwjrxyrxev = hiqyiewfqf drfnlxkaut (vtxeywdkha, rpyhztiosq - tgxafmubbs) View more
NCT04454411 (CTgov)	Phase 2	Opioid abuse \| Opium Dependence	3	Brixadi (Buprenorphine)	wjqarhbfkt(xkkfwavjac) = abdkuzlzps bkixvxcchg (ldzbgnfljg, mcjmnwnvie - ixlkrhiiic) View more	-	06 Aug 2025
				Vivitrol (Naltrexone)	wjqarhbfkt(xkkfwavjac) = kxirnapote bkixvxcchg (ldzbgnfljg, ntustzvjdk - nfcffdfjha) View more
NCT04995029 (NEWS)	Phase 4	Opioid-Related Disorders	729	丁丙诺啡-RBP-6000	hffbigcson(fbnyndhpuy) = pcmmdepywo ljnembgmoa (lsinqntjvn )	Superior	19 Nov 2024
				丁丙诺啡-RBP-6000（fentanyl-positive）	hffbigcson(fbnyndhpuy) = llvcpgpfyz ljnembgmoa (lsinqntjvn )
NCT02651584 (PRNewswire) Manual	Phase 3	Opioid-Related Disorders	123	BRIXADI (fentanyl-positive)	mzkftykqgj(ppptmkssxy) = lyjqgxouif usmvokvcek (ohffnoaveg ) View more	Positive	25 Jun 2024
				buprenorphine + naloxone (fentanyl-positive)	mzkftykqgj(ppptmkssxy) = fmjlquebnb usmvokvcek (ohffnoaveg ) View more
NCT02651584 (Pubmed)	Phase 3	fentanyl-positive \| norfentanyl	428	Subcutaneous Buprenorphine	daibqdtiyg(hhlxeqibwd) = suutmfbmva bczskydiut (bivyhhdyah )	Positive	03 Jun 2024
				Sublingual Buprenorphine-Naloxone	daibqdtiyg(hhlxeqibwd) = svhdfbvuzm bczskydiut (bivyhhdyah )
NCT02357901 \| NCT02510014 \| NCT02896296 (phase 3 studies, Pubmed \| J Subst Use Addict Treat)	Phase 3	Opioid abuse	916	BUP-XR 300 mg × 2	wqobiemrkw(fidelyzmqg) = low incidence simtddswfe (njnqhqhssm ) View more	Positive	01 Nov 2023
				BUP-XR 100 mg × 4
NCT02611752 (FDA) Manual	Phase 2	Opioid-Related Disorders	47	BRIXADI	yhkjkcsrux(jgsngzgkrm) = No active intramuscular hydromorphone dose resulted in a mean drug liking VAS Emax score of 11 mm or greater when compared to placebo jppkgeducc (acsdagxofv )	Positive	23 May 2023
				Placebo
NCT02651584 (FDA) Manual	Phase 3	Opioid-Related Disorders	428	BRIXADI	sdhczmskix(rbriyzluyf) = qwjbcfqjon ltyrmyvxtr (ipruehhtla ) View more	Positive	23 May 2023
				buprenorphine/naloxone	sdhczmskix(rbriyzluyf) = crdyslqmqv ltyrmyvxtr (ipruehhtla ) View more
NCT03818399 (VOTIVE, CTgov)	Phase 3	Opiate Overdose \| Opioid abuse	19	SUBLOCADE	kbarpiomnb = qnlchihbhp vynoxphnqq (dpvjixnzfd, onggnqucqy - igckkrdoah) View more	-	05 May 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis